Table 3 Immunohistochemistry and tumour characteristics in p53, SSTR-2a and CgA

p53

Total, rows

Negative

Het-pos.

Positive

p

n = 162 (100%)

n = 50 (30.9%)

n = 32 (19.8%)

n = 80 (49.4%)

SSTR-2a Negative

101 (62.3%)

29 (17.9%)

12 (7.4%)

60 (37.0%)

0.01*

SSTR-2a Het-pos.

19 (11.7%)

5 (3.1%)

7 (4.3%)

7 (4.3%)

SSTR-2a Positive

42 (25.9%)

16 (9.9%)

13 (8.0%)

13 (8.0%)

NET G3, Well diff.

14 (8.6%)

6 (3.7%)

5 (3.1%)

3 (1.9%)

0.05*

NEC, Poorly diff.

148 (91.4%)

44 (27.2%)

27 (16.7%)

77 (47.5%)

Small cell

21 (13.0%)

8 (4.9%)

5 (3.1%)

8 (4.9%)

0.53

Large cell

141 (87.0%)

42 (25.9%)

27 (16.7%)

72 (44.4%)

SSTR-2a

Total, rows

Negative

Het-pos.

Positive

p

n = 163 (100%)

n = 101 (62.0%)

n = 19 (11.7%)

n = 43 (26.4%)

CgA Negative

56 (34.4%)

45 (27.6%)

7 (4.3%)

4 (2.5%)

< 0.001*

CgA Het-pos.

40 (24.5%)

28 (17.2%)

3 (1.8%)

9 (5.5%)

CgA Positive

67 (41.1%)

28 (17.2%)

9 (5.5%)

30 (18.4%)

NET G3, Well diff.

14 (8.6%)

7 (4.3%)

0 (0%)

7 (4.3%)

0.08

NEC, Poorly diff.

149 (91.4%)

94 (57.7%)

19 (11.7%)

36 (22.1%)

Small cell

21 (12.9%)

11 (6.9%)

3 (1.8%)

7 (4.3%)

0.54

Large cell

142 (87.1%)

90 (55.2%)

16 (9.8%)

36 (22.1%)

CgA

Total, rows

Negative

Het-pos.

Positive

p

n = 163 (100.0%)

n = 56 (34.6%)

n = 40 (24.7%)

n = 67 (40.7%)

p53 Negative

50 (30.9%)

19 (11.7%)

7 (4.3%)

24 (14.8%)

0.03*

p53 Het-pos.

32 (19.8%)

6 (3.7%)

9 (5.6%)

17 (10.5%)

p53 Positive

80 (49.4%)

31 (19.1%)

24 (14.8%)

25 (15.4%)

NET G3, Well diff.

14 (8.6%)

1 (0.6%)

3 (1.8%)

10 (6.1%)

0.03*

NEC, Poorly diff.

149 (91.4%)

55 (33.7%)

37 (22.7%)

57 (35.0%)

Small cell

21 (12.9%)

12 (7.4%)

4 (2.5%)

5 (3.1%)

0.07

Large cell

142 (87.1%)

44 (27.0%)

36 (22.1%)

62 (38.0%)